PE20010066A1 - Polipeptido de proteina c activada - Google Patents

Polipeptido de proteina c activada

Info

Publication number
PE20010066A1
PE20010066A1 PE2000000398A PE0003982000A PE20010066A1 PE 20010066 A1 PE20010066 A1 PE 20010066A1 PE 2000000398 A PE2000000398 A PE 2000000398A PE 0003982000 A PE0003982000 A PE 0003982000A PE 20010066 A1 PE20010066 A1 PE 20010066A1
Authority
PE
Peru
Prior art keywords
substituted
amino acids
protein
thr
sequence
Prior art date
Application number
PE2000000398A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010066A1 publication Critical patent/PE20010066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

SE REFIERE A UN DERIVADO DE LA PROTEINA C QUE COMPRENDE LA SECUENCIA NO1 DE 419 AMINOACIDOS Y LOS AMINOACIDOS DE LA SECUENCIA 2 DE 461 AMINOACIDOS EN LAS QUE UNO O MAS DE LOS AMINOACIDOS DE LAS POSICIONES 194, 195, 228, 249, 254, 302, 316 ESTAN SUSTITUIDOS POR UN AMINOACIDO SELECCIONADO ENTRE SER, ALA, THR, HIS, LYS, ARG, ASN, ASP, GLU, GLY, GLN; DE PREFERENCIA LEU DE LA POSICION 194 ESTA SUSTITUIDA POR SER; LEU DE LA POSICION 194 ESTA SUSTITUIDA POR SER Y THR DE LA POSICION 254 ESTA SUSTITUIDA POR SER; CON LA CONDICION DE QUE EL AMINOACIDO 195 NO ESTA SUSTITUIDO POR ALA Y EL AMINOACIDO 254 NO ESTA SUSTITUIDO POR THR; DICHA SUSTITUCION ORIGINA UNA RESISTENCIA INCREMENTADA A SER INACTIVADO POR SERPINAS EN COMPARACION CON LA PROTEINA C HUMANA DE TIPO SILVESTRE ACTIVADA. TAMBIEN SE REFIERE A UN ADN RECOMBINANTE DE 1386 BASES, UN ACIDO NUCLEICO AISLADO QUE CODIFICA UN POLINUCLEOTIDO DE LA PROTEINA C HUMANA QUE CODIFICA POR LO MENOS EL 90% DE LOS AMINOACIDOS DE UNA SECUENCIA PROTEINICA. LA PROTEINA C INACTIVA A LOS FACTORES Va Y VIIIa EN LA CASCADA DE COAGULACION Y PUEDE SER UTIL COMO ANTICOAGULANTE
PE2000000398A 1999-04-30 2000-04-27 Polipeptido de proteina c activada PE20010066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
PE20010066A1 true PE20010066A1 (es) 2001-02-02

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000398A PE20010066A1 (es) 1999-04-30 2000-04-27 Polipeptido de proteina c activada

Country Status (11)

Country Link
EP (1) EP1090130A1 (es)
JP (1) JP2002542832A (es)
KR (1) KR20010053345A (es)
AR (1) AR029627A1 (es)
AU (1) AU4188500A (es)
BR (1) BR0006088A (es)
CA (1) CA2338799A1 (es)
HU (1) HUP0102444A3 (es)
IL (1) IL140326A0 (es)
PE (1) PE20010066A1 (es)
WO (1) WO2000066754A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326356A (zh) * 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
ATE286122T1 (de) * 2000-02-02 2005-01-15 Lilly Co Eli Protein c derivate
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001292308A1 (en) * 2000-09-30 2002-04-15 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインｃ配列

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
ATE321846T1 (de) * 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c

Also Published As

Publication number Publication date
HUP0102444A2 (hu) 2001-10-28
BR0006088A (pt) 2001-03-20
IL140326A0 (en) 2002-02-10
WO2000066754A1 (en) 2000-11-09
JP2002542832A (ja) 2002-12-17
AR029627A1 (es) 2003-07-10
EP1090130A1 (en) 2001-04-11
CA2338799A1 (en) 2000-11-09
AU4188500A (en) 2000-11-17
HUP0102444A3 (en) 2003-09-29
KR20010053345A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
RU2017135599A (ru) Белки, специфичные в отношении cd137
Andreu et al. N-terminal analogs of cecropin A: synthesis, antibacterial activity, and conformational properties
Jang et al. Halocidin: a new antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium
ATE417595T1 (de) Keratin-bindende polypeptide
ATE528014T1 (de) Polypeptid mit modifizierten kunitz domains
DE112006000677A5 (de) Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
DE60137587D1 (de) Antimikrobielle peptide und deren verwendung
PE20010066A1 (es) Polipeptido de proteina c activada
PA8426301A1 (es) Bikunina humana
AR058429A1 (es) Plantas de girasol resistentes a herbicidas, polinucleotidos que codifican proteinas de subunidad mayor de acetohidroxiacido sintetasa resistentes a herbicidas y metodos de uso
BRPI0512286A (pt) proteìnas quiméricas inibidoras da angiogênese e o uso
ATE406439T1 (de) Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken
DK110485A (da) Rensning, kloning og karakterisering af genet for interleukin 1
KR890000665A (ko) 크링글 치환이 있는 돌연변이체 t-PA
Shimokawa et al. Isolation, Sequence Analysis, and Biological Activity of Atrolysin E/D, the Non-RGD Disintegrin Domain fromCrotalus atroxVenom
ATE253636T1 (de) Mit smad wechselwirkende polypeptide und verwendungen davon
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
ES2044881T3 (es) Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
Satake et al. Rapid and efficient identification of cysteine-rich peptides by random screening of a venom gland cDNA library from the hexathelid spider Macrothele gigas
Arndt et al. The complete amino acid sequence of ribosomal protein H‐S11 from the archaebacterium Halobacterium marismortui
Balaji et al. Purification, structure determination and synthesis of covalitoxin-II, a short insect-specific neurotoxic peptide from the venom of the Coremiocnemis validus (Singapore tarantula)
BR112023026782A2 (pt) Formulações de proteínas quiméricas de fator viii e usos das mesmas
Sheng et al. Expression and characterization of a fibrinogenolytic enzyme from horsefly salivary gland
CO5210980A1 (es) PROTEINA V[sub E] Y SECUENCIAS DE ACIDO NUCLEICO, COMPOSICIONES, Y METODOS DE RESISTENCIA A PATOGENOS VEGETALES
ATE521635T1 (de) Physiologisch wirksamer komplex mit tnf aktivität

Legal Events

Date Code Title Description
FD Application declared void or lapsed